Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013

494 views

Published on

Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013

Published in: Business, Technology
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
494
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
11
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013

  1. 1. The market for injectable generics has been through a period of consolidation over the last few years as the leading companies have increased their presence through acq This is hardly surprising with a global injectables market in the region of US$144 billion. While the lion’s share remains with the innovative industry for the time chemical generics and will involve costly clinical trials. To date, only a handful of companies have gained regulatory approval for biosimilars in Europe, and the US is lik This report features in-depth reviews of 35 major products within specific therapy areas. Each product review examines mode of action, market approvals, competition, What this report covers: Executive Summary Injectable Drugs Market – Market Size and Opportunities Cancer – Hormonal Therapies, Chemotherapy, Monoclonal Antibodies, S The Injectable Generic and Biosimilar Drugs Report is the foolproof business resource for any industry executive that needs to fully understand the current products and table Of Content foreword executive Summary injectable Drugs Market market Size generic And Biosimilar Opportunities cancer hormonal Therapies faslodex (fulvestrant) mode Of Action approvals lifecycle Development competition Within The Marketplace patents market Outlook generic Company Activity zoladex (goserelin) mode Of Action approvals competition Within The Marketplace breast Cancer prostate Cancer patents market Outlook generic Company Activity europe north America chemotherapy eloxatin (oxaliplatin) mode Of Action approvals competition Within The Marketplace patents market Outlook generic Company Activity the ‘874 Patent Litigation: At Risk Launches And Subsequent Withdrawals europe taxotere (docetaxel) mode Of Action approvals competition Within The Marketplace patents market Outlook generic Company Activity europe us abraxane (paclitaxel Protein-bound Particles For Injectable Suspension; Albumin-bound) mode Of Action approvals competition Within The Marketplace patents market Outlook generic Company Activity alimta (pemetrexed) mode Of Action approvals lifecycle Development competition Within The Marketplace patents Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013
  2. 2. approvals competition Within The Marketplace patents market Outlook generic Company Activity monoclonal Antibodies rituxan/mabthera (rituximab) mode Of Action approvals competition Within The Marketplace patents market Outlook biosimilar Rituximab herceptin (trastuzumab) mode Of Action approvals competition Within The Marketplace breast Cancer gastric Cancer patents market Outlook biosimilar Trastuzumab avastin (bevacizumab) mode Of Action approvals competition Within The Marketplace patents market Outlook biosimilar Bevacizumab erbitux (cetuximab) mode Of Action approvals competition Within The Marketplace patents market Outlook biosimilar Cetuximab supportive Therapies g-csf neupogen (filgrastim) mode Of Action approvals competition Within The Marketplace patents market Outlook biosimilar Filgrastim europe usa rest Of The World neulasta (pegfilgrastim) mode Of Action approvals competition Within The Marketplace patents market Outlook biosimilar Pegfilgrastim diabetes humulin (insulin [rdna Origin]) mode Of Action approvals competition Within The Marketplace market Outlook humalog (insulin Lispro) mode Of Action approvals competition Within The Marketplace patents market Outlook lantus (insulin Glargine) mode Of Action approvals competition Within The Marketplace patents Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013
  3. 3. competition Within The Marketplace patents market Outlook levemir (insulin Detemir) mode Of Action approvals competition Within The Marketplace patents market Outlook novorapid & Novomix (insulin Aspart) mode Of Action approvals competition Within The Marketplace patents market Outlook biosimilar Human Insulin europe And Usa rest Of The World haematology epogen/eprex/procrit (epoetin Alfa) mode Of Action approvals competition Within The Marketplace patents market Outlook biosimilar Epoetin eu us aranesp (darbepoetin Alfa) mode Of Action approvals competition Within The Marketplace patents market Outlook biosimilars In Development lovenox/clexane (enoxaparin) mode Of Action approvals competition Within The Marketplace patents market Outlook generic Company Activity court Of Appeals Decision In Enoxaparin Suit immunology multiple Sclerosis copaxone (glatiramer Acetate) mode Of Action approvals competition Within The Marketplace patents market Outlook generics In Development sandoz And Momenta mylan And Natco Pharma avonex (interferon Beta-1a) mode Of Action approvals competition Within The Marketplace patents market Outlook rebif (interferon Beta-1a) mode Of Action approvals competition Within The Marketplace market Outlook betaferon/betaseron & Extavia (interferon Beta-1b) mode Of Action approvals competition Within The Marketplace patents market Outlook biosimilar Interferon Beta Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013
  4. 4. competition Within The Marketplace patents market Outlook biosimilar Etanercept humira (adalimumab) mode Of Action approvals competition Within The Marketplace patents market Outlook biosimilar Adalimumab remicade (infliximab) mode Of Action approvals competition Within The Marketplace patents market Outlook biosimilar Infliximab infection cubicin (daptomycin) mode Of Action approvals competition Within The Marketplace patents market Outlook generic Company Activity invanz (ertapenem) mode Of Action approvals competition Within The Marketplace patents market Outlook generic Company Activity tygacil (tygecycline) mode Of Action approvals competition Within The Marketplace patents market Outlook generic Company Activity synagis (palivizumab) mode Of Action approvals competition Within The Marketplace patents market Outlook biosimilar Development pegintron (peginterferon Alfa-2b) mode Of Action approvals competition Within The Marketplace patents market Outlook pegasys (pegylated-40k Interferon Alfa-2a) mode Of Action approvals competition Within The Marketplace patents market Outlook biosimilar Interferon Alfa major Competitors actavis products major Developments acquisitions & Agreements actavis Completes Acquisition Of Warner Chilcott litigation generic Diprivan Patent Challenge generic Velcade Patent Challenge akorn products acquisitions & Agreements Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013
  5. 5. american Regent products amphastar Pharmaceuticals products apotex products agreements stada Arzneimittel In-licenses Grastofil aurobindo Pharma products claris Lifesciences products recent Developments claris Lifesciences Completes Transfer Of Its Infusion Business For India And Emerging Markets to The Joint Venture With Otsuka Pharmaceutical And Mitsui claris Lifesciences To Sell On Its Own In The Us dr Reddy’s Laboratories products fresenius Kabi products product Recalls fresenius Kabi Recalls Benztropine Mesylate Injection fresenius Kabi Recalls Single Lot Of Magnesium Sulphate acquisitions app Acquires Three Products From Nexus agreements fresenius Kabi Begins Joint Venture On Iv Generics In Indonesia app And Teva Enter Gemcitabine Agreement litigation app Settles With The Medicines Company On Angiomax Patent Litigation hikma Pharmaceuticals products acquisitions & Agreements commercial Supply Contract With Unilife Medical Solutions hikma Enters Ethiopian Pharmaceutical Market Through Joint Venture With Midroc Group hospira products biosimilars acquisitions & Agreements hospira Signs Agreement With Q Core Medical For International Distribution Of Sapphire Infusion System hospira Acquires Api Manufacturing And R&d Facilities From Orchid litigation cubicin Patent Infringement Lawsuit mylan products acquisitions mylan’s Acquires Agila From Strides Arcolab litigation mylan And Teva Settle Copaxone Patent Litigation sagent Pharmaceuticals products product Recalls sagent Pharmaceuticals Announces Expanded Recall Of Vecuronium Bromide acquisitions And Agreements sagent Pharmaceuticals Announces Agreement To Acquire Remaining 50% Interest In Chinese manufacturing Joint Venture sagent Announces Amendment To Supply Agreement With Actavis sandoz Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013
  6. 6. litigation sandoz’s Generic Copaxone Does Not Infringe Teva’s Patent strides Arcolab products agreements pfenex And Agila Biotech In Joint Venture To Develop Biosimilars For Global Market sale Of Agila Specialties Division To Mylan strides And Eli Lilly Strategic Partnership To Deliver Generic Cancer Medicines In Emerging Markets strides Arcolab Sells Generic Pharmaceutical Operations In Australia And Southeast Asia To Watson pharmaceuticals sun Pharma products acquisitions & Agreements sun Pharma And Intrexon Joint Venture To Develop New Class Of Therapeutics For Ocular Diseases sun Pharma And Taro Announce Termination Of Proposed Merger sun Pharma To Acquire Url Generic From Takeda teva Pharmaceutical Industries products biopharmaceuticals And Biosimilars litigation teva And Mylan Settle Patent Dispute agreements teva And Lonza Discontinue Biologics Joint Venture teva Terminates Agreements With Curetech teva Enters Agreement With Handok wockhardt products appendix: Fda Anda Approvals sources index ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research ne needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013

×